Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. (a foreign private issuer) covers the month of March 2023, with a filing date of March 30, 2023. The document serves as a notice regarding the company's 2023 Annual General Meeting of Shareholders, scheduled for May 4, 2023, at the company's offices in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing, as it does not contain financial data.
Guidance, Outlook, and Corporate Actions
- Annual Meeting: The 2023 Annual General Meeting is set for May 4, 2023, at 3:00 p.m. Israel time.
- Record Date: Shareholders of record as of the close of business on April 4, 2023, are entitled to vote.
- Exhibits: The filing includes the Notice of Meeting (Exhibit 99.1), Proxy Statement (Exhibit 99.2), and Proxy Card (Exhibit 99.3).
- Registration Statements: The contents of the exhibits are incorporated by reference into the company's Form F-3 and Form S-8 registration statements.
Investor Verification Checklist
- Verify the specific agenda items and proposals detailed in the attached Proxy Statement (Exhibit 99.2).
- Confirm the record date of April 4, 2023, to determine voting eligibility.
- Review the voting procedures and required majorities for approval as outlined in the Notice of Meeting (Exhibit 99.1).
- Check for any subsequent filings that may supersede the information in this Form 6-K regarding the meeting.